Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC3678 | Temsirolimus |
| mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC50 values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1α-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis in vitro and vessel formation in vivo. Causes G1/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic. | |
| BCC3682 | PP242 |
| ATP-competitive mTORC1/mTORC2 inhibitor (IC50 = 8 nM). Displays selectivity for mTOR over other PI 3K family kinases (IC50 values are 0.102, 0.408, 1.27, 1.96 and 2.2 μM for p110γ, DNA-PK, p110δ, p110α and p110β respectively) and 215 further kinases. Displays modest inhibition of PKCα, JAK2, PKCβI, PKCβII and RET (IC50 values are 0.049, 0.110, 0.185, 0.198 and 0.224 μM respectively). Inhibits both S6K and 4EBP1 phosphorylation; activity causes a decrease in cap-dependent protein translation. Also triggers downregulation of cFLIPS and augments TRAIL-induced apoptosis of cancer cells. | |
| BCC3701 | NSC 74859 |
| Selectively inhibits STAT3 DNA-binding activity in vitro (IC50 values are 86, 160, and >300 μM for STAT3-STAT3, STAT1-STAT3 and STAT1-STAT1 DNA-binding activity respectively). Blocks growth and induces apoptosis preferentially in tumor cells that contain persistently active STAT3 in vitro and arrests tumor growth in a murine xenograft model in vivo. | |
| BCC3704 | GF 109203X |
| Very potent and selective inhibitor of protein kinase C, selective for the α and β1 isoforms (IC50 values are 0.0084, 0.0180, 0.210, 0.132, and 5.8 μM for α, β1, δ, ε and ζ isoforms respectively). Selective over MLCK, PKG and PKA (IC50 values are 0.6, 4.6, and 33 μM respectively). Potent antagonist at the 5-HT3 receptor (Ki = 29.5 nM). Anti-inflammatory in vivo. | |
| BCC3705 | Go 6983 |
| Broad spectrum protein kinase C (PKC) inhibitor (IC50 values are 7, 7, 6, 10, 60 and 20000 nM for PKCα, PKCβ, PKCγ, PKCδ, PKCζ and PKCμ respectively). Displays cardioprotective properties; reduces polymorphonuclear leukocyte adherence and infiltration following myocardial ischemia/reperfusion injury. Optimizes naïve human pluripotent stem cell growth and viability following naïve cell derivation from primed ESCs and iPSCs using naïve human stem cell medium (NHSM). | |
| BCC3706 | K-252c |
| Inhibitor of protein kinase C (IC50 = 2.45 μM) that displays ~ 10-fold selectivity over protein kinase A (IC50 = 25.7 μM). Also inhibits β-lactamase, malate dehydrogenase and chymotrypsin (IC50 values are 8, 8 and 10 μM respectively). Exhibits antiviral activity against GCV-sensitive and -resistant strains of human cytomegalovirus (HCMV) (IC50 values range from 0.13 - 0.32 μM). Shows no activity against herpes simplex virus (HSV). | |
| BCC3715 | A66 |
| Potent and selective PI 3-kinase p110α inhibitor (IC50 = 32 nM). Exhibits >100-fold selectivity for p110α over other PI 3-kinase isoforms. Inhibits Akt signaling and tumor growth in SK-OV-3 xenografts in mice. | |
| BCC3737 | Bexarotene |
| Potent and selective RXR agonist (EC50 values are 24, 25 and 33 nM for RXRβ, RXRγ and RXRα, respectively). Exhibits >300-fold selectivity for RXR over RAR receptors. Inhibits tumor cell invasion and migration in vitro, and inhibits metastasis and angiogenesis in mouse models. | |
